Targeting the Met signaling pathway in renal cancer.
Targeting the Met signaling pathway in renal cancer.
复制标题
DOI：
10.1586/era.09.43
复制
发表时间：
2009-06
影响因子：
3.3
通讯作者：
Bottaro DP
中科院分区：
文献类型：
--
作者：
Giubellino A;Linehan WM;Bottaro DP
肾细胞癌 (RCC) 是最常见的肾癌形式，占所有成人恶性肿瘤的 3%，且其发病率在过去 20 年中显着增加。 RCC 每年在美国夺走 13,000 人的生命，在全球范围内夺走超过 100,000 人的生命。对肾细胞癌分子基础的更好理解促进了新型且更具选择性的治疗方法的开发。 HGF 受体 Met 在 RCC 肿瘤发生中发挥着重要作用，最近它作为癌症治疗的分子靶点引起了广泛关注，并且几种选择性靶向该途径的药物目前正在进行临床试验。本综述将重点了解 Met 信号通路在肾癌中的作用，以及它如何促进有效和选择性候选药物的开发。
Renal cell carcinoma (RCC), the most common form of kidney cancer, accounts for 3% of all adult malignancies and its incidence has significantly increased over the last 20 years. RCC claims 13,000 lives annually in the USA and more than 100,000 worldwide. A better understanding of the molecular basis of RCC has facilitated the development of novel and more selective therapeutic approaches. An important role in RCC oncogenesis is played by the receptor for HGF, Met, which has attracted considerable attention, more recently as a molecular target for cancer therapy, and several drugs selectively targeting this pathway are now in clinical trials. This review will focus on efforts to understand the role of the Met signaling pathway in renal cancer and how this has contributed to the development of potent and selective drug candidates.
登录
查看更多内容
DOI：
10.1073/pnas.95.24.14379
发表时间：
1998-11-24
影响因子：
11.1
作者：
Bardelli, A;Longati, P;Comoglio, PM
通讯作者：
Comoglio, PM
影响因子：
8
作者：
Fan, SJ;Ma, YX;Rosen, EM
通讯作者：
Rosen, EM
影响因子：
56.9
作者：
BOTTARO, DP;RUBIN, JS;AARONSON, SA
通讯作者：
AARONSON, SA
影响因子：
4.3
作者：
Dussault, Isabelle;Bellon, Steven F.
通讯作者：
Bellon, Steven F.
影响因子：
56.9
作者：
DUAN, DR;PAUSE, A;KLAUSNER, RD
通讯作者：
KLAUSNER, RD